AstraZeneca is celebrating a trio of recent advancements for its portfolio in non-small cell lung cancer (NSCLC).Tagrisso, the company’s targeted tyrosine kinase inhibitor, produced a trial win in unresectable, stage 3 EGFR-mutated NSCLC. Monday, AZ described the drug’s performance in the study as an “overwhelming efficacy benefit.”Meanwhile, building on its success as a single agent […]
